

Special Issue

Pulmonary Infections: Pathogenesis and Antimicrobial Treatment

Message from the Guest Editor

Pulmonary infections remain a leading cause of morbidity and mortality worldwide, yet their underlying mechanisms are not completely understood. The severity of clinical presentation depends on a complex host-microbe interaction, immune resistance, tissue resilience, and changes in microbiome. In the last two years, we have witnessed a dramatic worldwide increase in hospitalizations for pneumonia caused by SARS-CoV-2 infection with high mortality rates. SARS-CoV-2 as well as other viral infections may also predispose patients to potentially fatal secondary bacterial or fungal infections. Furthermore, the increasing antimicrobial resistance is a major challenge as respiratory infections caused by multidrug-resistant bacteria are associated with a greater likelihood of inappropriate antimicrobial therapy and poor clinical outcomes. This Special Issue welcomes submissions of original and review articles that investigate the etiologies, pathogenesis, immunology, treatments, and outcomes of respiratory infections.

Guest Editor

Dr. Marija Vukoja

The Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica,
Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia

Deadline for manuscript submissions

closed (15 November 2024)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/130404

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)